ReviewToxins2020
Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease.
Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 86 citations in OpenAlex.
- Trial
- Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study.International urology and nephrology · 2021Trial
- Review
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- The Role of the Gut Microbiota and Uraemic Toxins in Vaccine Responsiveness Among People Receiving Maintenance Haemodialysis.Vaccines · 2026Article
- Muscle strength, neuromuscular function, and functional measures across stages of chronic kidney disease.BMC nephrology · 2026Article
- Predicting probiotic success: lessons from Oxalobacter and oxalate metabolism.NPJ biofilms and microbiomes · 2026Review
- Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease.Biomedicines · 2026Review
- A guide to uraemic toxicity.Nature reviews. Nephrology · 2026Review
- The gut-kidney axis in chronic kidney disease: a vicious cycle of microbial dysbiosis and uremic toxin accumulation.Frontiers in immunology · 2026Review
- Immune cells harbor their own microbiome-derived metabolome: a new layer of immunometabolic regulation.Frontiers in immunology · 2026Review
- Associations between hyperketonemia and the rumen metagenome and metabolome in Holstein cows during the first 2 weeks postpartum.Animal microbiome · 2025Article
- Synbiotic-driven modulation of the gut microbiota and metabolic functions related to obesity: insights from a human gastrointestinal model.BMC microbiology · 2025Article
- Chronic Kidney Disease and Osteoarthritis: Current Understanding and Future Research Directions.International journal of molecular sciences · 2025Review
- Renal aging and its consequences: navigating the challenges of an aging population.Frontiers in pharmacology · 2025Review
- UnravelingFrontiers in pharmacology · 2025Review
- Gut microbiome remodeling in chronic kidney disease: implications of kidney replacement therapies and therapeutic interventions.Frontiers in medicine · 2025Review
- The gut-kidney axis is regulated by astragaloside IV to inhibit cyclosporine A-induced nephrotoxicity.Frontiers in pharmacology · 2025Article
- Protein-bound uremic toxins as therapeutic targets for cardiovascular, kidney, and metabolic disorders.Frontiers in endocrinology · 2025Review
- A metagenome-wide study of the gut virome in chronic kidney disease.Theranostics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Several of the uremic toxins, which are difficult to remove by dialysis, originate from the gut bacterial metabolism. This opens opportunities for novel targets trying to decrease circulating levels of these toxins and their pathophysiological effects. The current review focuses on immunomodulatory effects of these toxins both at their side of origin and in the circulation. In the gut end products of the bacterial metabolism such as p-cresol, trimethylamine and H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.